TY  - JOUR
AU  - Djaileb, Loïc
AU  - Farolfi, Andrea
AU  - Rauscher, Isabel
AU  - Haghighatian, Mahan
AU  - Mercier, Alexis
AU  - Fendler, Wolfgang P
AU  - Hadaschik, Boris
AU  - Herrmann, Ken
AU  - Solnes, Lilja B
AU  - Rettig, Matthew
AU  - Weber, Manuel
AU  - Czernin, Johannes
AU  - Calais, Jeremie
AU  - Benz, Matthias R
AU  - Eiber, Matthias
AU  - Gafita, Andrei
TI  - Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
JO  - Journal of nuclear medicine
VL  - nn
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2025-02242
SP  - nn
PY  - 2025
N1  - epub / brief communication
AB  - Although tumor volume and new lesions (NLs) have been investigated previously as measures of response, the clinical impact of changes in tumor uptake on prostate-specific membrane antigen (PSMA) PET remains largely unknown. Methods: This multicenter retrospective study investigated the clinical impact of changes in tumor uptake and volume on PSMA PET during [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer (mCRPC). The primary outcomes were the associations of changes in SUVmax (ΔSUVmax) and SUVmean (ΔSUVmean), changes in total tumor volume (ΔTTV), and occurrence of NLs with prostate-specific antigen (PSA) progression-free survival (PSA-PFS) and overall survival (OS). The study included patients with mCRPC who received [177Lu]Lu-PSMA between 2014 and 2019. PSMA PET/CT was performed at baseline and after 2 cycles of therapy. Whole-body analyses (SUVmax, SUVmean, TTV, and NLs) were performed and calculated using qPSMA software. Results: In total, 124 patients with mCRPC (median age, 73 y; interquartile range, 67-76 y) were included in the study. Whole-body ΔTTV and the occurrence of NLs were significantly associated with shorter PSA-PFS (hazard ratio [HR], 5.7; 95
KW  - LuPSMA (Other)
KW  - PSMA PET (Other)
KW  - RECIP (Other)
KW  - metastatic castration-resistant prostate cancer (Other)
KW  - radiopharmaceutical therapy (Other)
KW  - response evaluation (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41167722
DO  - DOI:10.2967/jnumed.125.270239
UR  - https://inrepo02.dkfz.de/record/305583
ER  -